BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
106.07
+0.06 (+0.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close106.01
Open106.09
Bid0.00 x 1400
Ask0.00 x 1400
Day's Range104.15 - 106.72
52 Week Range75.81 - 106.72
Volume1,288,625
Avg. Volume1,187,143
Market Cap18.837B
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateOct 25, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est120.05
Trade prices are not sourced from all markets
  • ACCESSWIRE17 hours ago

    Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Tesaro

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...

  • PR Newswireyesterday

    BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

    FDA Approval Triggers $15 Million Payment BioMarin Entitled to Earn Mid-Single Digit Royalties on Future Sales SAN RAFAEL, Calif. , Oct. 16, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) ...

  • PR Newswire6 days ago

    BioMarin and Believe Limited Announce Selection of 25 High School Students to Perform in First-of-its-Kind 'Hemophilia: The Musical'

    SAN RAFAEL, Calif., Oct. 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced the twenty-five high school students from across the U.S. who will participate in 'Hemophilia: The Musical,' a first-of-its-kind theatrical production written and informed by their unique experiences of life as a young person with a bleeding disorder. A live stream of the performance will be made available at BreakingThroughHemophilia.com.

  • PR Newswire6 days ago

    Forbes Names BioMarin Among World's Best Employers

    SAN RAFAEL, Calif., Oct. 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that Forbes' named the company to its list, Global 2000:  World's Best Employers.  It is ranked within the top 300 out of a total of 2000 companies and fifth among the nine biotech companies also named. "BioMarin is a pioneer in developing treatments for rare disease, which requires a level of comfort in encountering the unknown.  People who are attracted to BioMarin are energized by the challenge of doing what has never been done before scientifically and by the potential to change the course of a disease," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin.

  • Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
    American City Business Journals9 days ago

    Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area

    Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.

  • PR Newswire14 days ago

    BioMarin to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, October 25 at 4:30pm ET

    SAN RAFAEL, Calif. , Oct. 4, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference ...

  • With Hemlibra, Roche seeks to break into tight hemophilia circle
    Reuters15 days ago

    With Hemlibra, Roche seeks to break into tight hemophilia circle

    Swiss drugmaker Roche (ROG.S) is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder. Roche's Hemlibra, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win the U.S. Food and Drug Administration's blessing for use in nearly all patients this week. To hit $5 billion global annual sales that some analysts forecast, Hemlibra must wrest business away from hemophilia giants like Shire (SHP.L), Bayer (BAYGn.DE), Novo Nordisk (NOVOb.CO) and Octapharma, whose "clotting factors" are now standard for people who lack proteins that stop bleeding.

  • An Investor’s Overview of BioMarin Pharmaceutical Stock
    Market Realist19 days ago

    An Investor’s Overview of BioMarin Pharmaceutical Stock

    BioMarin Pharmaceutical (BMRN) stock closed at $97.97 yesterday, which represents ~29% growth from its 52-week low of $75.81 on April 6. This year, BioMarin stock has grown ~10%, rising from $88.84 to $97.97. The stock hit a 52-week high of $106.20 on August 7.

  • Here Are the Key Products in Sage’s GABA Receptor Portfolio
    Market Realist24 days ago

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    As discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders through two different programs: GABA receptor systems and NMDA receptor systems.

  • Estimates and Recommendations for Shire on September 19
    Market Realist27 days ago

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • PR Newswire29 days ago

    BioMarin to Participate in Two Investor Conferences in October

    Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2 in New York City SAN RAFAEL, Calif. , Sept. 19, 2018 ...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • Markitlast month

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • Analysts Remain Bullish on BioMarin Pharmaceutical
    Market Realistlast month

    Analysts Remain Bullish on BioMarin Pharmaceutical

    Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.

  • BioMarin Pharmaceutical and Its Promising Research Pipeline
    Market Realistlast month

    BioMarin Pharmaceutical and Its Promising Research Pipeline

    Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).

  • When Will BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Become Profitable?
    Simply Wall St.last month

    When Will BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Become Profitable?

    BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN): BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company’s loss has recentlyRead More...

  • Why Analysts Remain Bullish on Sangamo Therapeutics
    Market Realistlast month

    Why Analysts Remain Bullish on Sangamo Therapeutics

    Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.

  • Estimates and Recommendations for Bluebird Bio on September 6
    Market Realistlast month

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realistlast month

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • Sangamo's Zinc Fingers Fail Again. Time to Walk Away?
    Motley Foollast month

    Sangamo's Zinc Fingers Fail Again. Time to Walk Away?

    Here's what investors need to know about the disappointing results Sangamo announced recently.

  • Investor's Business Dailylast month

    How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease

    Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.

  • How’s Alkermes Positioned Financially in September?
    Market Realistlast month

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.

  • PR Newswirelast month

    BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018

    Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250) SAN RAFAEL, Calif. , Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the ...